Skip to content

Comparison of injection of ketorolac and lidocaine with ketorolac in the surgical incision site in pain intensity after caesarean section

Comparison of injection of ketorolac and lidocaine with ketorolac in the surgical incision site in pain intensity after caesarean section

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240528061936N1
Enrollment
34
Registered
2024-12-03
Start date
2024-12-05
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The amount of pain in the caesarean section wound.

Interventions

Intervention 1: Injection of Ktorlak drug, half a milligram per kilogram of a person's weight from Alborz Daru pharmaceutical company, at the incision site of cesarean surgery. Intervention 2: Interve

Sponsors

Zahedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: pregnant woman candidate for caesarean section Age range from 18 to 50 years Satisfaction of the expectant mother

Exclusion criteria

Exclusion criteria: Lack of personal satisfaction Age range above 65 or below 18 A patient with a psychological disorder A patient with diabetes A patient with cardiovascular disease Patients with preeclampsia and eclampsia Emergency caesarean section

Design outcomes

Primary

MeasureTime frame
Pain score based on vas questionnaire. Timepoint: After the operation in the recovery room and 6 and 24 hours after the operation in the obstetrics and gynecology department. Method of measurement: Vas pain questionnaire.

Secondary

MeasureTime frame
Complications of drugs based on Iowa Questionnaire. Timepoint: In the obstetrics and gynecology department after surgery. Method of measurement: Based on the iowa questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzad Alishir

Zahedan University of Medical Sciences

Farzadalishir@gmail.com+98 902 502 7878

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026